Ignite Creation Date:
2024-05-06 @ 6:04 PM
Last Modification Date:
2024-10-26 @ 2:41 PM
Study NCT ID:
NCT05533619
Status:
COMPLETED
Last Update Posted:
2023-11-18
First Post:
2022-09-02
Brief Title:
Risk Factors and Machine Learning Model for Proton Pump Inhibitor Related Acute Kidney Injury
Sponsor:
Qianfoshan Hospital
Organization:
Qianfoshan Hospital
Study Overview
Official Title:
Analysis of Risk Factors of Proton Pump Inhibitor Related Acute Kidney Injury in Hospitalized Patients and Developments of Machine Learning Model
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Recent evidence concerns acute kidney injury AKI following proton pump inhibitor PPI application Few actual studies have compared the incidence risk factors and predictive models of AKI associated with PPI The present study was a single-center retrospective study The researchers retrospectively analyzed data from patients who received PPI medications between January 2018 and December 2020 PPI drugs included omeprazole esomeprazole rabeprazole and pantoprazole The primary outcome of the study was AKI as defined by kidney disease improving global outcomes KDIGO Secondary outcomes included length of hospital stay hospital costs and continuous renal replacement therapy Independent risk factors associated with AKI were identified by univariate analysis and multifactorial logistic regression analysis P 005 Logistic regression models were constructed based on the variables obtained from the analysis Internal validation of the model was performed by the ten-fold cross-validation method Model discriminatory power was assessed by the area under the curve AUC of the receiver operating characteristic curve ROC The study aims to develop a PPI-related AKI prediction model based on an electronic medical record system that can be used to predict AKI in hospitalized patients and contribute to the early prevention diagnosis and treatment of AKI ultimately reducing morbidity and improving prognosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None